142 related articles for article (PubMed ID: 30222483)
1. Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphoma: Standard of Care After the PETAL Study?
Gisselbrecht C
J Clin Oncol; 2018 Sep; ():JCO1800498. PubMed ID: 30222483
[No Abstract] [Full Text] [Related]
2. Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.
Hüttmann A; Rekowski J; Müller SP; Hertenstein B; Franzius C; Mesters R; Weckesser M; Kroschinsky F; Kotzerke J; Ganser A; Bengel FM; La Rosée P; Freesmeyer M; Höffkes HG; Hertel A; Behringer D; Prange-Krex G; Griesshammer M; Holzinger J; Wilop S; Krohn T; Raghavachar A; Maschmeyer G; Brink I; Schroers R; Gaska T; Bernhard H; Giagounidis A; Schütte J; Dienst A; Hautzel H; Naumann R; Klein A; Hahn D; Pöpperl G; Grube M; Marienhagen J; Schwarzer A; Kurch L; Höhler T; Steiniger H; Nückel H; Südhoff T; Römer W; Brinkmann M; Ose C; Alashkar F; Schmitz C; Dürig J; Hoelzer D; Jöckel KH; Klapper W; Dührsen U
Ann Hematol; 2019 Apr; 98(4):897-907. PubMed ID: 30610279
[TBL] [Abstract][Full Text] [Related]
3. Molecular characteristics of diffuse large B-cell lymphoma in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin lymphomas (PETAL) trial: correlation with interim PET and outcome.
Richter J; Hüttmann A; Rekowski J; Schmitz C; Gärtner S; Rosenwald A; Hansmann ML; Hartmann S; Möller P; Wacker HH; Feller A; Thorns C; Müller S; Dührsen U; Klapper W
Blood Cancer J; 2019 Aug; 9(9):67. PubMed ID: 31427567
[No Abstract] [Full Text] [Related]
4. Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma: results from the PETAL trial.
Broecker-Preuss M; Becher-Boveleth N; Müller SP; Hüttmann A; Hanoun C; Grafe H; Richter J; Klapper W; Rekowski J; Bockisch A; Dührsen U
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2611-2621. PubMed ID: 34708297
[TBL] [Abstract][Full Text] [Related]
5. Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial.
Dührsen U; Müller S; Hertenstein B; Thomssen H; Kotzerke J; Mesters R; Berdel WE; Franzius C; Kroschinsky F; Weckesser M; Kofahl-Krause D; Bengel FM; Dürig J; Matschke J; Schmitz C; Pöppel T; Ose C; Brinkmann M; La Rosée P; Freesmeyer M; Hertel A; Höffkes HG; Behringer D; Prange-Krex G; Wilop S; Krohn T; Holzinger J; Griesshammer M; Giagounidis A; Raghavachar A; Maschmeyer G; Brink I; Bernhard H; Haberkorn U; Gaska T; Kurch L; van Assema DME; Klapper W; Hoelzer D; Geworski L; Jöckel KH; Scherag A; Bockisch A; Rekowski J; Hüttmann A;
J Clin Oncol; 2018 Jul; 36(20):2024-2034. PubMed ID: 29750632
[TBL] [Abstract][Full Text] [Related]
6. Impact of complete surgical resection on outcome in aggressive non-Hodgkin lymphoma treated with immunochemotherapy.
Schmitz C; Rekowski J; Müller SP; Farsijani N; Hertenstein B; Franzius C; von Verschuer U; La Rosée P; Freesmeyer M; Wilop S; Krohn T; Raghavachar A; Ganser A; Bengel FM; Prange-Krex G; Kroschinsky F; Kotzerke J; Giagounidis A; Dührsen U; Hüttmann A
Cancer Med; 2020 Nov; 9(22):8386-8396. PubMed ID: 32926763
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas--the PETAL trial.
Dührsen U; Hüttmann A; Jöckel KH; Müller S
Leuk Lymphoma; 2009 Nov; 50(11):1757-60. PubMed ID: 19863177
[TBL] [Abstract][Full Text] [Related]
8. PET-guided treatment for personalised therapy of Hodgkin lymphoma and aggressive non-Hodgkin lymphoma.
Phillips EH; Iype R; Wirth A
Br J Radiol; 2021 Nov; 94(1127):20210576. PubMed ID: 34520242
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography/computed tomography in the management of Hodgkin and B-cell non-Hodgkin lymphoma: An update.
Juweid ME; Mueller M; Alhouri A; A-Risheq MZ; Mottaghy FM
Cancer; 2021 Oct; 127(20):3727-3741. PubMed ID: 34286864
[No Abstract] [Full Text] [Related]
10. Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial.
Schmitz C; Hüttmann A; Müller SP; Hanoun M; Boellaard R; Brinkmann M; Jöckel KH; Dührsen U; Rekowski J
Eur J Cancer; 2020 Jan; 124():25-36. PubMed ID: 31710995
[TBL] [Abstract][Full Text] [Related]
11. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
Borchmann P; Plütschow A; Kobe C; Greil R; Meissner J; Topp MS; Ostermann H; Dierlamm J; Mohm J; Thiemer J; Sökler M; Kerkhoff A; Ahlborn M; Halbsguth TV; Martin S; Keller U; Balabanov S; Pabst T; Vogelhuber M; Hüttmann A; Wilhelm M; Zijlstra JM; Moccia A; Kuhnert G; Bröckelmann PJ; von Tresckow B; Fuchs M; Klimm B; Rosenwald A; Eich H; Baues C; Marnitz S; Hallek M; Diehl V; Dietlein M; Engert A
Lancet Oncol; 2021 Feb; 22(2):223-234. PubMed ID: 33539742
[TBL] [Abstract][Full Text] [Related]
12. Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial.
Schmitz C; Rekowski J; Müller SP; Hertenstein B; Franzius C; Ganser A; Bengel FM; Kroschinsky F; Kotzerke J; La Rosée P; Freesmeyer M; Hoeffkes HG; Hertel A; Behringer D; Mesters R; Weckesser M; Mahlmann S; Haberkorn U; Martens U; Prange-Krex G; Brenner W; Giagounidis A; Moeller R; Runde V; Sandmann M; Hautzel H; Wilop S; Krohn T; Dürk H; Heike M; Alashkar F; Brinkmann M; Trenn G; Wacker D; Kreisel-Büstgens C; Bernhard H; Heil G; Larisch R; Kurch L; Jöckel KH; Hoelzer D; Klapper W; Boellaard R; Dührsen U; Hüttmann A
Hematol Oncol; 2020 Aug; 38(3):244-256. PubMed ID: 32067259
[TBL] [Abstract][Full Text] [Related]
13. Pretransplant FDG-PET in aggressive non-Hodgkin lymphoma: systematic review and meta-analysis.
Adams HJ; Kwee TC
Eur J Haematol; 2017 Apr; 98(4):337-347. PubMed ID: 27943422
[TBL] [Abstract][Full Text] [Related]
14. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.
Casasnovas RO; Bouabdallah R; Brice P; Lazarovici J; Ghesquieres H; Stamatoullas A; Dupuis J; Gac AC; Gastinne T; Joly B; Bouabdallah K; Nicolas-Virelizier E; Feugier P; Morschhauser F; Delarue R; Farhat H; Quittet P; Berriolo-Riedinger A; Tempescul A; Edeline V; Maisonneuve H; Fornecker LM; Lamy T; Delmer A; Dartigues P; Martin L; André M; Mounier N; Traverse-Glehen A; Meignan M
Lancet Oncol; 2019 Feb; 20(2):202-215. PubMed ID: 30658935
[TBL] [Abstract][Full Text] [Related]
15. Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs.
El-Galaly TC; Mylam KJ; Brown P; Specht L; Christiansen I; Munksgaard L; Johnsen HE; Loft A; Bukh A; Iyer V; Nielsen AL; Hutchings M
Haematologica; 2012 Jun; 97(6):931-6. PubMed ID: 22207683
[TBL] [Abstract][Full Text] [Related]
16. A Prospective, Multicenter Study of Involved-Field Radiation Therapy With Autologous Stem Cell Transplantation for Patients With Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma (ALLG HDNHL04/TROG 03.03).
Wirth A; Prince HM; Roos D; Gibson J; O'Brien P; Zannino D; Khodr B; Stone JM; Davis S; Hertzberg M
Int J Radiat Oncol Biol Phys; 2019 Apr; 103(5):1158-1166. PubMed ID: 30553941
[TBL] [Abstract][Full Text] [Related]
17. Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial.
Seifert R; Kersting D; Rischpler C; Sandach P; Ferdinandus J; Fendler WP; Rahbar K; Weckesser M; Umutlu L; Hanoun C; Hüttmann A; Reinhardt HC; von Tresckow B; Herrmann K; Dührsen U; Schäfers M
Leukemia; 2022 Dec; 36(12):2845-2852. PubMed ID: 36241697
[TBL] [Abstract][Full Text] [Related]
18. Synchronous or metachronous lymphoma and metastatic cutaneous squamous cell carcinoma in the head and neck region: a diagnostic and management dilemma.
Kader I; Leavers B; Shashinder S; Wylie B; Chi KK; Sundaresan P
J Laryngol Otol; 2016 Jul; 130 Suppl 4():S45-9. PubMed ID: 27488337
[TBL] [Abstract][Full Text] [Related]
19. Pretransplantation [18-F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non-Hodgkin lymphoma undergoing reduced-intensity conditioning followed by allogeneic stem cell transplantation.
Dodero A; Crocchiolo R; Patriarca F; Miceli R; Castagna L; Ciceri F; Bramanti S; Frungillo N; Milani R; Crippa F; Fallanca F; Englaro E; Corradini P
Cancer; 2010 Nov; 116(21):5001-11. PubMed ID: 20665491
[TBL] [Abstract][Full Text] [Related]
20. F-18 FDG PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: a meta-analysis.
Chen YK; Yeh CL; Tsui CC; Liang JA; Chen JH; Kao CH
Clin Nucl Med; 2011 Jul; 36(7):553-9. PubMed ID: 21637057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]